The InSiGHT 2021 Jersey City/NYC will be a 3.5 day meeting, similar in structure to previous InSiGHT meetings. Our planned Plenary Sessions will invite the highest level of peer reviewed abstracts to address key areas. These will include:
Personal and Familial Risk assessment with a focus on effective Family Health History Ascertainment, cancer prevention, advances in surveillance technologies and clinical protocols;
Novel germline and somatic genetic mechanisms predisposing to hereditary GI malignancy;
State of the Art Novel gene discovery including the current science of “missing heritability”;
Novel genomic based therapies;
Advances in surgical and endoscopic management of hereditary GI malignancies;
Challenging clinical case discussions;
The impact of gene panel testing on the genetic and clinical management of the hereditary GI syndromes;
Additional sessions will be provided to meet the clinical navigation, optimal quality of life and psychological support needs of affected individuals and their families.
The program will also provide opportunities through peer reviewed content and special invited speakers to explore how InSiGHT can optimally position itself to lead globally on key issues such as promoting clinical awareness,education and research on the hereditary GI syndromes. How will we actually deliver on our vision and “promise” to fully integrate all of the continents on our planet in our efforts? How can we best provide effectiveenduring mentorship of the next generation of clinicians and scientists who will take on the clinical and scientific challenges of the hereditary GI syndromes? What steps can we take, as a global organization, to secure sustainability and growth? We will also tackle a very special issue; over 20 years after the cloning of the DNA mismatch repair (MMR) genes, how can InSiGHT rekindle an active relationship with big science including, of course genomics, genetics, and epigenetics to help us advance our collective understanding of the biology of the hereditary GI malignancy syndromes? This is essential to attract “the best and the brightest” of future generations to our scientific and clinical arena.
Please select a director to view their bio.
Please select a committee member to view their bio.
For questions and comments please email: